UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The past and future of CD33 as therapeutic target in acute myeloid leukemia

Blood reviews, 2014-07, Vol.28 (4), p.143-153

2014

Volltextzugriff (PDF)

The Broad Anti-AML Activity of the CD33/CD3 BiTE Antibody Construct, AMG 330, Is Impacted by Disease Stage and Risk

PloS one, 2015-08, Vol.10 (8), p.e0135945-e0135945

2015

Volltextzugriff (PDF)

Relationship between CD33 expression, splicing polymorphism, and in vitro cytotoxicity of gemtuzumab ozogamicin and the CD33/CD3 BiTE® AMG 330

Haematologica (Roma), 2019-02, Vol.104 (2), p.e59-e62

2019

Volltextzugriff (PDF)

Efficient long-term multilineage engraftment of CD33-edited hematopoietic stem/progenitor cells in nonhuman primates

Molecular therapy. Methods & clinical development, 2023-12, Vol.31, p.101121-101121, Article 101121

2023

Volltextzugriff (PDF)

AKT signaling as a novel factor associated with in vitro resistance of human AML to gemtuzumab ozogamicin

PloS one, 2013-01, Vol.8 (1), p.e53518

2013

Volltextzugriff (PDF)

Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML

Blood, 2014-01, Vol.123 (4), p.554-561

2014

Volltextzugriff (PDF)

Engineering resistance to CD33-targeted immunotherapy in normal hematopoiesis by CRISPR/Cas9-deletion of CD33 exon 2

Leukemia, 2019-03, Vol.33 (3), p.762-808

2019

Volltextzugriff (PDF)

Simultaneous multiple interaction T-cell engaging (SMITE) bispecific antibodies overcome bispecific T-cell engager (BiTE) resistance via CD28 co-stimulation

Leukemia, 2018-05, Vol.32 (5), p.1239-1243

2018

Volltextzugriff (PDF)

Significance of expression of ITGA5 and its splice variants in acute myeloid leukemia: A report from the children's oncology group

American journal of hematology, 2013-08, Vol.88 (8), p.694-702

2013

Volltextzugriff (PDF)

Increased Basal cAMP-dependent Protein Kinase Activity Inhibits the Formation of Mesoderm-derived Structures in the Developing Mouse Embryo

The Journal of biological chemistry, 2002-07, Vol.277 (30), p.27294-27304

2002

Volltextzugriff (PDF)

Erratum to: High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group

Journal of hematology and oncology, 2016-11, Vol.9 (1), p.133-133, Article 133

2016

Volltextzugriff (PDF)

Development of [211At]astatine-based anti-CD123 radioimmunotherapy for acute leukemias and other CD123+ malignancies

Leukemia, 2022-06, Vol.36 (6), p.1485-1491

2022

Volltextzugriff (PDF)

Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin

Frontiers in bioscience, 2013-06, Vol.18 (4), p.1311

2013

Volltextzugriff (PDF)

The Bruton’s tyrosine kinase inhibitor ibrutinib abrogates bispecific antibody‐mediated T‐cell cytotoxicity

British journal of haematology, 2020-04, Vol.189 (1), p.e9-e13

2020

Volltextzugriff (PDF)

The CD33 splice isoform lacking exon 2 as therapeutic target in human acute myeloid leukemia

Leukemia, 2020-09, Vol.34 (9), p.2479-2483

2020

Volltextzugriff (PDF)

[211At]astatine-based anti-CD22 radioimmunotherapy for B-cell malignancies

Leukemia & lymphoma, 2023-06, Vol.ahead-of-print (ahead-of-print), p.1-5

2023

Volltextzugriff (PDF)

Targeting the membrane-proximal C2-set domain of CD33 for improved CD33-directed immunotherapy

Leukemia, 2021-09, Vol.35 (9), p.2496-2507

2021

Volltextzugriff (PDF)

Cullin 5 destabilizes Cas to inhibit Src-dependent cell transformation

Journal of cell science, 2014-02, Vol.127 (Pt 3), p.509-520

2014

Volltextzugriff (PDF)

Optimizing Siglec-8-Directed Immunotherapy for Eosinophilic and Mast Cell Disorders

Cancers, 2024-10, Vol.16 (20), p.3476

2024

Volltextzugriff (PDF)

Anti-apoptotic BCL-2 family proteins confer resistance to calicheamicin-based antibody-drug conjugate therapy of acute leukemia

Leukemia & lymphoma, 2020-10, Vol.61 (12), p.2990-2994

2020

Volltextzugriff (PDF)

Restriction of Src Activity by Cullin-5

Current biology, 2009-01, Vol.19 (2), p.157-162

2009

Volltextzugriff (PDF)

Expression and functional characterization of CD33 transcript variants in human acute myeloid leukemia

Oncotarget, 2016-07, Vol.7 (28), p.43281-43294

2016

Volltextzugriff (PDF)

Src activation decouples cell division orientation from cell geometry in mammalian cells

Biomaterials, 2018-07, Vol.170, p.82-94

2018

Volltextzugriff (PDF)

1 – 25 von 828

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(720)
Mit Volltextzugriff
(720)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(508)
Life Sciences & Biomedicine
(378)
Humans
(293)
Female
(139)
Male
(137)
Animals
(130)
Biological And Medical Sciences
(114)
Medical Sciences
(84)
Physical Sciences
(83)
Middle Aged
(73)
Medicin Och Hälsovetenskap
(68)
Adult
(65)
Technology
(58)
Oncology
(55)
Biochemistry & Molecular Biology
(54)
Aged
(53)
Mice
(48)
Neurosciences & Neurology
(46)
Fundamental And Applied Biological Sciences. Psychology
(40)
Chemistry
(39)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

The past and future of CD33 as therapeutic target in acute myeloid leukemia

The Broad Anti-AML Activity of the CD33/CD3 BiTE Antibody Construct, AMG 330, Is Impacted by Disease Stage and Risk

Relationship between CD33 expression, splicing polymorphism, and in vitro cytotoxicity of gemtuzumab ozogamicin and the CD33/CD3 BiTE® AMG 330

Efficient long-term multilineage engraftment of CD33-edited hematopoietic stem/progenitor cells in nonhuman primates

AKT signaling as a novel factor associated with in vitro resistance of human AML to gemtuzumab ozogamicin

Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML

Engineering resistance to CD33-targeted immunotherapy in normal hematopoiesis by CRISPR/Cas9-deletion of CD33 exon 2

Simultaneous multiple interaction T-cell engaging (SMITE) bispecific antibodies overcome bispecific T-cell engager (BiTE) resistance via CD28 co-stimulation

Significance of expression of ITGA5 and its splice variants in acute myeloid leukemia: A report from the children's oncology group

Increased Basal cAMP-dependent Protein Kinase Activity Inhibits the Formation of Mesoderm-derived Structures in the Developing Mouse Embryo

Erratum to: High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group

Development of [211At]astatine-based anti-CD123 radioimmunotherapy for acute leukemias and other CD123+ malignancies

Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin

The Bruton’s tyrosine kinase inhibitor ibrutinib abrogates bispecific antibody‐mediated T‐cell cytotoxicity

The CD33 splice isoform lacking exon 2 as therapeutic target in human acute myeloid leukemia

[211At]astatine-based anti-CD22 radioimmunotherapy for B-cell malignancies

Targeting the membrane-proximal C2-set domain of CD33 for improved CD33-directed immunotherapy

Cullin 5 destabilizes Cas to inhibit Src-dependent cell transformation

Optimizing Siglec-8-Directed Immunotherapy for Eosinophilic and Mast Cell Disorders

Anti-apoptotic BCL-2 family proteins confer resistance to calicheamicin-based antibody-drug conjugate therapy of acute leukemia

Restriction of Src Activity by Cullin-5

Expression and functional characterization of CD33 transcript variants in human acute myeloid leukemia

Src activation decouples cell division orientation from cell geometry in mammalian cells

COVA4231, a potent CD3/CD33 bispecific FynomAb with IgG-like pharmacokinetics for the treatment of acute myeloid leukemia

Preclinical Characterization of the Anti-Leukemia Activity of the CD33/CD16a/NKG2D Immune-Modulating TriNKET ® CC-96191

Suchergebnisse filtern